Last reviewed · How we verify
SCT1000
At a glance
| Generic name | SCT1000 |
|---|---|
| Also known as | Recombinant 14 valent Human Papillomavirus Vaccine, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells) |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years (PHASE3)
- A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years (PHASE2)
- A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT1000 CI brief — competitive landscape report
- SCT1000 updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI